financial results for the first half of FY2025 were driven by year-over-year impact from generic erosion of VYVANSE, as anticipated. In the second half, we expect this generic erosion impact to moderate and Growth and Launch Product growth to increase. Our updated outlook for the full year reflects the effects of transactional FX fluctuations and impairment losses on intangible assets associated with the gamma delta T-cell therapy platform—with strong OPEX management offsetting changes in product mix.

“We are confident in our business fundamentals as we look to the second half of this transitional year for Takeda.”

FINANCIAL HIGHLIGHTS for FY2025 H1 Ended September 30, 2025






(Billion yen, except percentages and per share amounts)









FY2025 H1



FY2024 H1


=*=*=*=*=*=
当前为第3/19页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页